The Amended Federal Hemp Definition: What It Covers and When

By Cannible Editorial

2026-08-10

As of August 20, 2026, the amended federal definition describes hemp as Cannabis sativa L., and any part of the plant—including seeds and its derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers—with total tetrahydrocannabinols, including tetrahydrocannabinolic acid, of not more than 0.3 percent on a dry-weight basis. The amendment is stated to take effect 365 days after enactment; the evidence supplied here does not provide the enactment date, so it does not establish the resulting calendar effective date. The position can change after August 20, 2026. 1

This article is general information, not individualized legal, medical, business, or compliance advice. Whether any of it applies to a particular person, product or business depends on the facts and on applicable state law; consult a qualified professional.

The statutory definition of hemp

The amended definition includes industrial hemp. It also states that hemp does not include viable seeds from a Cannabis sativa L. plant exceeding the specified total tetrahydrocannabinols concentration in the plant on a dry-weight basis. 1

The definition excludes intermediate hemp-derived cannabinoid products containing cannabinoids that the plant cannot naturally produce, or cannabinoids that the plant can naturally produce but that were synthesized or manufactured outside the plant. It also excludes intermediate products with more than 0.3 percent combined total of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and other cannabinoids with similar effects—or marketed as having similar effects—on humans or animals as a tetrahydrocannabinol, as determined by the Secretary of Health and Human Services. 1

The definition separately excludes intermediate hemp-derived cannabinoid products marketed or sold as a final product or directly to an end consumer for personal or household use. 1

What counts as industrial hemp

The statute defines industrial hemp as hemp grown for the stalk, fiber produced from the stalk, or another non-cannabinoid derivative, mixture, preparation, or manufacture of the stalk. It also includes hemp grown for the whole grain, oil, cake, nut, hull, or another non-cannabinoid compound, derivative, mixture, preparation, or manufacture of the seeds. 1

The industrial-hemp category also covers hemp grown to produce microgreens or other edible hemp-leaf products intended for human consumption when derived from an immature hemp plant grown from seeds that do not exceed the statutory total-tetrahydrocannabinols threshold. It includes plants that do not enter the stream of commerce and are intended to support hemp research at an institution of higher education or an independent research institute, as well as viable seeds produced solely to make or manufacture materials described in the industrial-hemp definition. 1

Hemp-derived cannabinoid product categories

A hemp-derived cannabinoid product is defined as an intermediate or final product derived from hemp other than industrial hemp, containing cannabinoids in any form and intended for human or animal use through any means of application or administration, including inhalation, ingestion, or topical application. 1

An intermediate hemp-derived cannabinoid product is one that is not yet in the final form or preparation marketed or intended for human or animal use or consumption. The category also includes a powder, liquid, tablet, oil, or other product form intended or marketed to be mixed, dissolved, formulated, or otherwise added to or prepared with or into another substance before administration or consumption. 1

A final hemp-derived cannabinoid product is subject to a separate exclusion when it contains cannabinoids that the plant cannot naturally produce, or cannabinoids that the plant can naturally produce but that were synthesized or manufactured outside the plant. It is also excluded when it contains more than 0.4 milligrams per container of combined total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and other cannabinoids with similar effects—or marketed as having similar effects—on humans or animals as a tetrahydrocannabinol, as determined by the Secretary of Health and Human Services. 1

The definition does not include a drug that is the subject of an application approved under section 505(c) or 505(j) of the Federal Food, Drug, and Cosmetic Act. 1

Dry weight and per-container limits are different

The 0.3 percent threshold is a dry-weight standard. It applies to the general definition of hemp and to the viable-seed exclusion, which refers to the concentration in the plant on a dry-weight basis. 1

The 0.4 milligram limit is not a dry-weight threshold. It applies to a final hemp-derived cannabinoid product and is measured as a combined total per container. The statute defines container as the innermost wrapping, packaging, or vessel directly touching and enclosing the final product for retail sale to consumers, including a jar, bottle, bag, box, packet, can, carton, or cartridge. Bulk shipping containers and outer wrappings that are not essential for final retail delivery or sale to an end consumer for personal or household use are excluded from that definition. 1

The evidence does not provide the additional information and specificity about the term container that the statute directs the Food and Drug Administration to publish within 90 days of enactment, so this article does not add further rules about how a particular package would be measured. 1

Timing and the separate pending measure

The amendment itself states that it becomes effective 365 days after enactment. That effective-date rule is distinct from any announcement date, and the evidence supplied here does not give the amendment’s enactment date. 1

A separate measure would provide that, until December 11, 2026, the amendments made by section 781 would apply only to the two statutory exclusions involving cannabinoids that the plant cannot naturally produce: one for intermediate hemp-derived cannabinoid products and one for final hemp-derived cannabinoid products. The evidence does not establish that this measure became enacted law. 2 3

On August 8, 2026, the Senate held a roll-call vote on a procedural motion concerning S.Amdt. 6747 to S.Amdt. 6732 to H.R. 6500. The supplied record states that a procedural motion is not a vote on final passage and is not enactment into law; it does not establish a final legislative outcome for the measure. 3

What this does not establish

This federal definition does not determine the law of any state. The evidence supplied here does not say whether any particular item owned, sold, or offered to an adult consumer falls within the definition or complies with state law. 4

The federal discussion of marijuana scheduling is a separate matter. The supplied regulator material states that parts of Cannabis sativa have been controlled under the Controlled Substances Act and that “Marihuana” is listed in Schedule I; those statements do not replace or expand the narrower statutory categories and thresholds described above. 4

Regulator statements about delta-8 THC

Separately from the statutory definition, the FDA states that delta-8 THC is one of more than 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the plant, and that concentrated amounts are typically manufactured from hemp-derived cannabidiol. The FDA also states that delta-8 THC has psychoactive and intoxicating effects similar to delta-9 THC. 5

The FDA states that delta-8 THC products have not been evaluated or approved by the agency for safe use in any context. That is a regulator statement about delta-8 THC products; it is not a determination in this article that any particular product is included in or excluded from the amended federal hemp definition. 5